Quinine Should Not Be Used for Restless Legs Syndrome
Quinine is not recommended for the treatment of RLS and carries serious safety risks that outweigh any potential benefit. The most recent 2025 American Academy of Sleep Medicine (AASM) clinical practice guideline does not include quinine as a treatment option for RLS, and the FDA explicitly warns against its use for conditions other than malaria 1, 2.
FDA Warning Against Off-Label Use
The FDA has issued a boxed warning specifically addressing the use of quinine for nocturnal leg cramps (a condition often confused with RLS), stating that quinine may cause "unpredictable serious and life-threatening hematologic reactions including thrombocytopenia and hemolytic-uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP)" in addition to hypersensitivity reactions, QT prolongation, serious cardiac arrhythmias including torsades de pointes, and other serious adverse events 2.
The FDA explicitly states: "The risk associated with the use of quinine sulfate capsules in the absence of evidence of its effectiveness for treatment or prevention of nocturnal leg cramps, outweighs any potential benefit in treating and/or preventing this benign, self-limiting condition" 2.
Evidence of Ineffectiveness
Research demonstrates that quinine lacks efficacy for RLS:
A 1991 double-blind crossover trial of hydroquinine (a quinine derivative) versus placebo in 59 patients with RLS showed no significant differences in efficacy between the two groups on any outcome measure, including daily questionnaires and immobilization tests 3.
A 2008 UK cohort study of 8,621 newly diagnosed RLS patients found that use of medications not approved for RLS treatment (including quinine) was not associated with a reduction in clinical symptoms or healthcare resource utilization 4.
Current Evidence-Based Treatment Recommendations
The 2025 AASM guidelines provide clear first-line treatment options that should be used instead of quinine 1:
Strong Recommendations (First-Line):
- Gabapentin enacarbil (strong recommendation, moderate certainty) 1
- Gabapentin (strong recommendation, moderate certainty) 1
- Pregabalin (strong recommendation, moderate certainty) 1
- IV ferric carboxymaltose in patients with appropriate iron status (strong recommendation, moderate certainty) 1
Conditional Recommendations (Second-Line):
- Ferrous sulfate for appropriate iron status (conditional recommendation, moderate certainty) 1
- Extended-release oxycodone and other opioids (conditional recommendation, moderate certainty) 1
- Dipyridamole (conditional recommendation, low certainty) 1
Clinical Pitfalls to Avoid
Do not confuse RLS with nocturnal leg cramps, as these are distinct conditions with different pathophysiology and treatment approaches 1. Quinine has historically been used for leg cramps (though now contraindicated), but this does not translate to RLS treatment 2.
Avoid dopamine agonists as first-line therapy (pramipexole, ropinirole, rotigotine), as the AASM now suggests against their standard use due to the risk of augmentation, which occurs in 7-10% of patients annually 1, 5, 6.
Serious Safety Concerns with Quinine
If a patient has been taking quinine, be aware of these potentially fatal complications 2:
- Thrombocytopenia (can be fatal; chronic renal impairment associated with TTP has been reported)
- Hemolytic anemia (particularly in G6PD deficiency)
- QT prolongation and torsades de pointes (concentration-dependent)
- Hypersensitivity reactions including ITP, TTP, and HUS
Quinine is contraindicated in patients with prolonged QT interval, myasthenia gravis, optic neuritis, and known hypersensitivity to quinine, mefloquine, or quinidine 2.